Andrii Buvailo, PhDThe ‘Why’, ‘How’ and ‘When’ of AI In Pharma Industry“It is not the strongest of the species that survives, nor the most intelligent, but the one most adaptable to change” — Leon C. Megginson5d ago5d ago
Andrii Buvailo, PhDGoogle’s Novel TPUs Now Power AI Foundation Model for RNA ResearchGoogle’s 6th generation Trillium TPUs are now powering arguably the largest RNA-focused AI foundation model on the market.May 18May 18
Andrii Buvailo, PhDHype Around AlphaFold 3: Results vs LimitationsWhat does the AlphaFold 3 launch mean for the drug discovery community?May 14May 14
Andrii Buvailo, PhDThe First Human Brain Implant Malfunctioned, But It's OKNeuralink, a company owned by Elon Musk, reported that an implant in a human subject malfunctioned.May 9May 9
Andrii Buvailo, PhDModerna Enhances Partnership with OpenAI in a Bet on ChatGPT and Custom GPTsWe’ve been using custom GPTs for almost a year now. And it is hard to overestimate the increase in productivity on many repetitive tasks.May 7May 7
Andrii Buvailo, PhDBig Pharma Hints: AI is Already Impacting Clinical ResearchHow big pharma and smaller companies apply AI to improve clinical trialsMay 1May 1
Andrii Buvailo, PhD4 Ways Big Data and Machine Learning Transform Drug DiscoveryHow does “magic” happen?Apr 27Apr 27
Andrii Buvailo, PhDAn Unnoticed Event That May Symbolize the Future of Drug TestingToday I’d like to hightlight a quite interesting (a symbolic even?) event that went relatively unnoticed by media and science commentators…Apr 25Apr 25
Andrii Buvailo, PhDA New AI Drug Discovery Startup Launched with $1 Billion in CapitalAs first reported by Endpoints News, Xaira Therapeutics has emerged as one of the most significantly funded new entrants in the biotech…Apr 23Apr 23
Andrii Buvailo, PhDAI Foundation Models in Biotech: New ParadigmWhat are foundation models anyway, and why is there all the buzz lately?Apr 19Apr 19